National Cardiogenic Shock Initiative: 1 Year Later

Video Chapters:The Impact of The Cardiogenic Shock Initiative (NCSI):...

The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial

Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses...

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...

How to Better Evaluate, Identify and Manage Shock Patients

Recently, Abiomed’s platform of Impella® heart pumps received FDA approval for the treatment of patients experiencing cardio...

The FDA’s Shock Indication for the Impella

The FDA recently granted Abiomed approval to expand Impella™ 2.5 PMA to treat patients suffering cardiogenic shock follo...

Significance of FDA Approval of Impella for Cardiogenic Shock

Listen to Dr. William W. O’Neill, Medical Director for the Center for Structural Heart Disease at Henry Ford Hospital, discus...